Lipoprotein (a) cholesterol burden predicts atherosclerotic risk in patients with elevated lipoprotein a

Abstract Funding Acknowledgements Type of funding sources: Private hospital(s). Main source(s): Mayo Clinic Department Laboratory Medicine and Pathology. Background Elevated lipoprotein(a) [Lp(a)] is associated with increased risk for atherosclerotic cardiovascular disease (ASCVD). Treatment patients elevated Lp(a) usually includes marked reduction in low density lipoprotein cholesterol (LDL-C). However, there are uncertainties about whether all increases equivalent relationship. Purpose The aim this investigation was to stratify mass [Lp(a)-M] based on (Lp(a)-C) measurements. We assessed coronary artery (CAD) by angiogram major adverse cardiac events (MACE) a cohort (≥30mg/dL) over 15 year followup. Methods Electrophoretic immunologic assays were used measure Lp(a)-C Lp(a)-M, respectively. Univariate multivariate logistic regression analysis employed test association between CAD Lp(a)-M (≥30mg/dL). relationship time evaluated using cox analysis. Receiver operator curve (ROC) analyses identify optimal cutoff values C predicting our model. Results analyzed 179 Lp(a)-M. Cutoff 3.3mg/dL 42.1mg/dL optimally predicted an ROC Of these patients, 84 found have < (low Lp(a)-C), while 95 had levels ≥ (high Lp(a)-C). High identified angiography univariate (OR = 2.17, 95% CI 1.18 – 4.00, p 0.013) 3.36, 1.64 6.89, 0.001) models controlling traditional factors. In high also MACE (HR 2.38, 1.19 4.75, 0.01) Lp(a)-M) not 1.68, 0.82 3.44, 0.15) (Table 1, Figure 1). remained significantly correlated after adjusting When included model together, maintained its significance failed predict MACE, indicating that stronger predictor than Conclusion This study demonstrates approximately 2.5 times more likely encounter when compared Lp(a)-C. Our suggests can be those at higher risk.